Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $185.42 USD
Change Today -2.77 / -1.47%
Volume 1.1M
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - $215.73
52 Week Low
09/16/14 - $135.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments. The CHC segment offers OTC products, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, and other healthcare products, as well as vitamins, minerals, and dietary supplements; and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health; vitamins, minerals, and supplements; cough, cold, and allergy; personal care and derma-therapeutics; lifestyle; and anti-parasite areas. This segment serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx Pharmaceuticals segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment provides Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients that are used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.

13,500 Employees
Last Reported Date: 08/13/15
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Mulls Acquisitions

Perrigo Company Public Limited Company (NYSE:PRGO) is looking for acquisitions. Joe Papa, Chief Executive Officer of Perrigo said that the company generally looks at acquisitions in the $100 million to $1 billion range. The official admitted that Perrigo could look at even larger deals. Joe Papa added that in addition to deals to bolster the range of products Perrigo offers to U.S. drugstores and grocers, the company could also seek deals in adult nutrition, diabetes or wound care.

Perrigo Company plc Announces Quarterly Dividend Payable on September 15, 2015

Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.125 per share, payable on September 15, 2015 to shareholders of record on August 28, 2015.

Perrigo Company Public Limited Company Announces Consolidated Unaudited Earnings Results for the Second Quarter Ended June 27, 2015; Records Goodwill Impairment Charge for the Second Quarter of 2015; Provides Earnings Guidance for the Third Quarter and Full Year 2015

Perrigo Company Public Limited Company announced consolidated unaudited earnings results for the second quarter ended June 27, 2015. For the quarter, the company reported net sales of $1,531.6 million compared with $1,144.2 million for the same period a year ago. Operating income was $226.9 million compared with $197.4 million for the same period a year ago. Income before income taxes was $157.4 million compared with $165.5 million for the same period a year ago. Net income was $56.4 million or $0.38 per diluted share compared with $131.7 million or $0.98 per diluted share for the same period a year ago. Adjusted operating income was $436.9 million compared with $324.6 million for the same period a year ago. Adjusted income before tax was $385.9 million compared with $296.2 million for the same period a year ago. Adjusted net income was $320.3 million or $2.18 per diluted share compared with $234.1 million or $1.74 per diluted share for the same period a year ago. For the quarter, the company recorded goodwill impairment charge of $6.8 million. The company anticipates both the third and fourth calendar quarter tax rates to increase to approximately 18.5% due to the inclusion of estimated earnings before tax from Omega Pharma. This jump in the rate is a function of the accounting rules surrounding annualizing effective tax rate. The company expects third calendar quarter 2015 adjusted net income to grow between 30% and 35% over the comparable 2014 period. The company continues to expect calendar year 2015 adjusted earnings per diluted share range of $7.50 to $8.00, an increase of 20% to 28% over calendar 2014 adjusted earnings per share. While the adjusted annual effective tax rate is still expected to be approximately 17% for the full calendar year 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $185.42 USD -2.77

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $78.70 USD -0.30
Hospira Inc $89.93 USD +0.01
Mead Johnson Nutrition Co $78.57 USD +0.20
Mylan NV $50.37 USD -1.12
Sun Pharmaceutical Industries Ltd 886.45 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation PRGO Industry Range
Price/Earnings 100.0x
Price/Sales 5.9x
Price/Book 2.5x
Price/Cash Flow 211.9x
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at